
Melissa Lechner MD PhD
Diabetes, Lipid Metabolism, Thyroid
Assistant Professor of Medicine
Join to View Full Profile
10833 LeConte Ave, 57-145Los Angeles, CA 90095
Phone+1 310-794-7555
Fax+1 310-794-7555
Dr. Lechner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Melissa G. Lechner, MD, PhD is an Assistant Professor of Medicine in the Division of Endocrinology, Diabetes, and Metabolism at the UCLA David Geffen School of Medicine. Her clinical and research interests are related to endocrine disease resulting from cancer immunotherapy (onco-endocrinology) and advanced thyroid cancer. She established the Onco-Endocrinology clinic at UCLA to care for patients with endocrine side effects from cancer immunotherapy and targeted therapies. She also has expertise in thyroid nodules (including biopsy).
Dr. Lechner leads multiple prospective clinical trials at UCLA studying thyroid disease and cancer immunotherapy. She has received funding from the American Thyroid Association, Endocrine Fellows Foundation, and National Institutes of Health for her research and has been invited to speak nationally and internationally on the role of the immune system in cancer. She has published articles in Thyroid, The Journal of Clinical Endocrinology and Metabolism, The Journal of Immunology, Cancer, and Clinical Cancer Research, including original research and invited reviews, and serves on the National Comprehensive Cancer Network of Management of Immunotherapy Toxicity Side Effects guidance panel.
After finishing her combined MD and PhD training in the joint USC Keck School of Medicine/Cal Tech physician-scientist training program, Dr. Lechner completed residencies in internal medicine and pediatrics at Brigham and Women's Hospital and Boston Children's Hospital of the Harvard Medical School. In 2018, she joined UCLA as a clinical fellow in endocrinology and post-doctoral researcher in the prestigious Specialty Training and Advanced Research (STAR) program. In 2020, Dr. Lechner joined the faculty at UCLA.
Clinical Expertise
- Thyroid disease, Basic Science Research, Clinical and translational research, Onco-Endocrinology, Thyroiditis, Thyroid nodules and thyroid cancer, Immune toxicities of cancer immunotherapy
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 2018 - 2020
- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2015 - 2018
- Keck School of Medicine of the University of Southern CaliforniaClass of 2014
Certifications & Licensure
- CA State Medical License 2018 - 2026
- MA State Medical License 2017 - 2020
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Publications & Presentations
PubMed
- Polyfunctional T follicular helper cells drive checkpoint-inhibitor diabetes and are targeted by JAK inhibitor therapy.Nicole L Huang, Jessica G Ortega, Kyleigh Kimbrell, Joah Lee, Lauren N Scott
JCI Insight. 2025-07-08 - Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer.Alexis LeVee, Esther Peluso, Melissa G Lechner, Nora Ruel, Joanne Mortimer
The Oncologist. 2025-06-04 - UTX Coordinates TCF1 and STAT3 to Control Progenitor CD8+ T cell Fate in Autoimmune Diabetes.Ho-Chung Chen, Hsing Hui Wang, Karl B Shpargel, Lisa A Kohn, David Sailer
Biorxiv. 2025-05-19
Press Mentions
- Breakthrough Drug Could Prevent Deadly Side Effect of Cancer TreatmentJuly 10th, 2025
- HMN 2025: How Common Autoimmune Drug Could Assist Reverse Immunotherapy-Induced DiabetesJuly 9th, 2025
- Common Autoimmune Drug May Help Reverse Immunotherapy-Induced DiabetesJuly 8th, 2025
- Join now to see all
Grant Support
- Targets for Prevention of Autoimmune Toxicities from Checkpoint ImmunotherapyAramont Charitable FoundationPresent
- Mechanisms of Thyroid Autoimmunity in Checkpoint ImmunotherapyNational Institutes of Health (NIDDK)Present
- Role of Recent Thymic T Cells in Immune Checkpoint Inhibitor ThyroiditisAmerican Thyroid AssociationPresent
Professional Memberships
- Member
- National Comprehensive Cancer NetworkMember
External Links
- Research Grouphttps://maureensulab.wixsite.com/maureensugroup
- Pubmed Bibliographyhttps://www.ncbi.nlm.nih.gov/myncbi/melissa.lechner.1/bibliography/public/
- ATA Researchhttps://www.thyroid.org/professionals/research-grants/thyroid-research-recipients-2020/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: